Does Blue Cross Blue Shield of Massachusetts Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that blocks Factor Xa, reducing clot formation in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and patients undergoing hip or knee replacement surgery. The FDA approved apixaban in 2012 for stroke prevention in nonvalvular atrial fibrillation and expanded approvals followed for DVT/PE indications [1].

Clinical Evidence Supporting Apixaban Use

Coverage decisions often track clinical evidence. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; P<0.001) and cut major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001) in patients with atrial fibrillation [2]. The AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional therapy for acute VTE treatment and caused significantly less major bleeding (0.6% vs. 1.8%; P<0.001) [3].

Why Formulary Placement Changes Your Cost

Because Eliquis has no FDA-approved generic, insurers place it on brand tiers. A Tier 3 placement means you pay a preferred-brand copay. A Tier 4 placement means a higher non-preferred copay. The American Heart Association estimates that cost-related non-adherence to cardiovascular medications affects roughly 25% to 30% of patients prescribed them [4], making formulary tier directly relevant to whether patients actually take the drug.

How BCBS MA Formularies Work

Blue Cross Blue Shield of Massachusetts uses a multi-tier formulary structure across its commercial PPO, HMO, and Medicare Advantage product lines. Each plan publishes a "Drug List" (formulary) updated quarterly, and Eliquis placement can shift between formulary reviews.

Tier Structure Overview

Most BCBS MA commercial plans use a 4-to-5 tier system:

• Tier 1: Generic drugs (lowest copay, often $5 to $15)
• Tier 2: Preferred generics or low-cost brands
• Tier 3: Preferred brand-name drugs
• Tier 4: Non-preferred brand-name drugs
• Tier 5 (some plans): Specialty drugs

Eliquis sits at Tier 3 on many BCBS MA commercial plans and at Tier 4 on plans that have renegotiated their formulary. On BCBS MA Medicare Advantage plans, Eliquis has appeared at the formulary's "Preferred Brand" stage, though exact stage assignment varies by plan year.

Finding Your Specific Plan's Eliquis Tier

The most reliable method is to use the BCBS MA online drug cost tool at bluecrossma.org, enter your plan ID, and search "apixaban" or "Eliquis." The tool shows current tier, prior authorization (PA) requirements, quantity limits, and estimated cost. Calling the member services number on the back of your insurance card also works; ask specifically: "What tier is apixaban (Eliquis) on my formulary, and does it require prior authorization?"

Prior Authorization Requirements for Eliquis Under BCBS MA

Prior authorization (PA) is one of the most common barriers patients face with Eliquis on BCBS MA plans. PA means your prescribing physician must submit clinical documentation before the plan will cover the drug at the in-network benefit rate [5].

When PA Is Typically Required

BCBS MA PA criteria for apixaban generally require documentation of:

1. An FDA-approved diagnosis (nonvalvular atrial fibrillation, DVT, PE, or surgical prophylaxis)
2. Prescriber attestation that the patient has a contraindication to warfarin, has failed or is intolerant of warfarin, or has a clinical reason that a DOAC is preferred
3. Relevant lab values or imaging confirming the diagnosis (e.g., echocardiogram or Holter findings for atrial fibrillation; duplex ultrasound for DVT)

The 2023 ACC/AHA Atrial Fibrillation Guideline (Circulation, 2023) gives DOACs including apixaban a Class I recommendation over warfarin for most patients with nonvalvular atrial fibrillation [6]. Citing this guideline in a PA request strengthens the clinical justification.

How Long PA Approval Takes

Under Massachusetts General Law Chapter 176O, insurers must respond to standard PA requests within 3 business days and urgent (expedited) requests within 24 hours [7]. BCBS MA's own policy targets a 72-hour turnaround for standard requests. If the PA is denied, you have the right to an internal appeal and then an external independent review.

Step Therapy Policies

Some BCBS MA plans include a step therapy requirement. This means the plan may require a trial of a lower-cost anticoagulant (historically warfarin or a different DOAC) before authorizing Eliquis. Massachusetts law (M.G.L. Chapter 176O, Section 11B) permits step therapy but also requires an exception process when step therapy is clinically inappropriate [7]. Your physician can request a step therapy exception by documenting:

• Clinical contraindication to the required first-step drug
• Prior failure or adverse reaction to the required drug
• That delaying Eliquis would cause irreversible harm

How Much Does Eliquis Cost With BCBS MA Coverage?

Cost depends on your plan's tier placement, your deductible status, and whether you use preferred pharmacy networks. The figures below are estimates derived from BCBS MA's published drug cost tools and publicly available plan documents; always verify with your specific plan.

Commercial Plan Cost Estimates

| Coverage Stage | Estimated 30-Day Cost | |---|---| | Before deductible met (full cost) | $550 to $620 | | Tier 3 copay (deductible met) | $47 to $75 | | Tier 4 copay (deductible met) | $90 to $150 | | Mail-order 90-day supply (Tier 3) | $105 to $180 |

Medicare Advantage Cost Estimates

For BCBS MA Medicare Advantage plans, Eliquis cost typically follows the plan's Coverage Gap (Donut Hole) rules under Part D. The Inflation Reduction Act of 2022 caps Medicare Part D out-of-pocket drug costs at $2,000 per year starting in 2025 [8]. This cap benefits patients on chronic apixaban therapy who previously faced thousands of dollars in annual costs during the coverage gap.

Using Manufacturer Copay Assistance

Bristol-Myers Squibb and Pfizer co-market Eliquis and offer a co-pay savings program. Commercially insured patients (not Medicare or Medicaid) may pay as little as $10 per month. Eligibility and program terms are available at eliquis.com. The program does not apply to federal program beneficiaries, but Medicare patients may qualify for the Extra Help (Low Income Subsidy) program through the Social Security Administration, which can reduce Part D cost-sharing substantially [9].

What to Do If BCBS MA Denies Eliquis Coverage

A denial is not the end. Multiple formal pathways exist to reverse a denial or obtain coverage through alternative channels.

Step 1: Internal Appeal

Request a formal written denial (the Explanation of Benefits or denial letter) and file an internal appeal within the timeframe specified in your plan documents, typically 180 days from the denial date. Your physician must submit a letter of medical necessity citing:

• The specific FDA-approved indication (reference the FDA prescribing information) [1]
• Relevant trial data (ARISTOTLE [2] or AMPLIFY [3]) demonstrating clinical superiority or safety advantage
• The ACC/AHA Class I guideline recommendation [6]

Step 2: External Independent Review

If the internal appeal is denied, Massachusetts law entitles you to an external review by an independent review organization (IRO) certified by the Massachusetts Division of Insurance [7]. IRO decisions are binding on the insurer. External reviews for life-threatening conditions can be expedited to 72 hours.

Step 3: Massachusetts Division of Insurance Complaint

Filing a complaint with the Massachusetts Division of Insurance (mass.gov/doi) creates a formal record and often prompts faster insurer response. The Division can compel compliance if the insurer is found to have violated M.G.L. Chapter 176O.

Step 4: Patient Assistance Programs

If appeals fail or take time, the Bristol-Myers Squibb Patient Assistance Foundation may provide free Eliquis to uninsured or underinsured patients meeting income criteria. Your prescriber's office can initiate the application.

Apixaban Dosing and the Indications That Trigger Coverage

BCBS MA PA reviewers assess whether the prescribed dose matches the FDA-approved indication. Mismatches between dose and indication are a common reason for initial PA denial.

FDA-Approved Doses by Indication

| Indication | Standard Dose | Notes | |---|---|---| | Nonvalvular atrial fibrillation | 5 mg twice daily | Reduce to 2.5 mg BID if 2 of 3 criteria: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL | | DVT/PE treatment (acute, days 1-7) | 10 mg twice daily | Then 5 mg BID | | DVT/PE treatment (after day 7) | 5 mg twice daily | Long-term treatment | | DVT/PE extended treatment | 2.5 mg twice daily | After 6 months of treatment | | Post-hip replacement prophylaxis | 2.5 mg twice daily for 35 days | Start 12 to 24 hours post-op | | Post-knee replacement prophylaxis | 2.5 mg twice daily for 12 days | Start 12 to 24 hours post-op |

Source: FDA Eliquis prescribing information [1].

The dose reduction criteria for atrial fibrillation (two of three: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) are embedded in the FDA label and must be documented in PA requests when the 2.5 mg BID dose is prescribed for afib rather than the 5 mg BID standard dose [1].

Clinical Guidelines That Support Coverage Arguments

When your physician is drafting a PA letter or appeal, citing authoritative guidelines carries weight with PA reviewers.

ACC/AHA Atrial Fibrillation Guideline (2023)

The 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation states: "For patients with AF and elevated stroke risk, anticoagulation with a DOAC is recommended in preference to warfarin in DOAC-eligible patients (Class I; Level of Evidence A)" [6]. Apixaban is specifically listed among the four approved DOACs, and its bleeding profile from ARISTOTLE supports its preferred status in patients with higher bleeding risk [2][6].

ASH 2020 VTE Guidelines

The American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism recommend DOACs over vitamin K antagonists for DVT and PE in patients without cancer (conditional recommendation, moderate certainty of evidence) [10]. For cancer-associated thrombosis, the guidelines suggest a DOAC such as apixaban may be preferable in patients at high bleeding risk from gastrointestinal or genitourinary malignancies [10].

CHEST 2022 Antithrombotic Guidelines

The American College of Chest Physicians (CHEST) 2022 antithrombotic guidelines recommend apixaban as one of the first-line options for VTE treatment, citing its net clinical benefit profile and the AMPLIFY trial data (N=5,395, major bleeding 0.6% vs. 1.8% for conventional therapy) [3][11].

Comparing Eliquis to Other DOACs on the BCBS MA Formulary

Understanding where Eliquis sits relative to other DOACs can inform formulary exception requests. If a lower-tier DOAC is therapeutically comparable for your indication, PA reviewers may require a trial of that drug first.

DOAC Formulary Comparison Framework for BCBS MA Plans

| Drug | Generic Name | Typical BCBS MA Tier | PA Usually Required | Key Differentiator | |---|---|---|---|---| | Eliquis | Apixaban | Tier 3 to 4 | Yes (many plans) | Twice-daily dosing; lowest major bleeding in head-to-head data | | Xarelto | Rivaroxaban | Tier 3 to 4 | Yes (many plans) | Once-daily dosing; food-dependent absorption | | Pradaxa | Dabigatran | Tier 3 to 4 | Yes (some plans) | Renal clearance 80%; avoid if CrCl <30 mL/min | | Savaysa | Edoxaban | Tier 3 to 4 | Yes (some plans) | Must follow 5-10 days parenteral anticoagulation | | Warfarin | Warfarin | Tier 1 | No | Requires INR monitoring; many drug and food interactions |

When a step therapy requirement mandates warfarin first, your physician can argue that the patient's lifestyle (e.g., irregular diet, frequent travel) or comorbidities (e.g., prior labile INR on warfarin) make DOAC therapy clinically appropriate from the outset [6][11]. The ACC/AHA Class I recommendation for DOACs over warfarin in eligible patients provides direct guideline support [6].

Special Populations and Coverage Considerations

Patients With Renal Impairment

Apixaban requires dose adjustment at creatinine clearance <25 mL/min per the FDA label. Patients on dialysis were excluded from ARISTOTLE, and prescribing in end-stage renal disease is off-label, which may trigger additional PA scrutiny [1][2]. The 2018 KDIGO commentary notes that evidence for DOACs in dialysis patients with atrial fibrillation is insufficient to make a definitive recommendation [12].

Patients With Cancer-Associated Thrombosis

BCBS MA plans may apply different PA criteria when Eliquis is prescribed for cancer-associated VTE versus idiopathic VTE. The CARAVAGGIO trial (N=1,170) showed apixaban was non-inferior to dalteparin for cancer-associated VTE recurrence (5.6% vs. 7.9%; hazard ratio 0.63; P<0.001 for non-inferiority) without increased major bleeding [13]. Citing CARAVAGGIO in a PA request for an oncology patient strengthens the clinical rationale.

Post-Surgical Prophylaxis

For orthopedic prophylaxis indications, PA requirements tend to be lower because the indication is discrete, the duration is fixed (12 or 35 days), and the FDA-labeled dose is unambiguous. Some BCBS MA plans cover surgical prophylaxis doses without PA or with a simplified PA pathway.

Pharmacy Network and Preferred Pharmacy Savings

BCBS MA plans typically designate preferred pharmacy networks where cost-sharing is lower. CVS Pharmacy is part of the BCBS MA preferred network for many commercial products. Using a non-preferred pharmacy may increase your tier copay by $10 to $30 per fill. Mail-order pharmacy (90-day supply) reduces per-dose cost and is required by some BCBS MA plans for maintenance medications after two or three retail fills.

The FDA's guidance on safe medication dispensing does not restrict mail-order for apixaban; Eliquis is not a controlled substance and has no REMS (Risk Evaluation and Mitigation Strategy) program [1][5].

Key Massachusetts-Specific Legal Protections

Massachusetts law provides stronger patient protections than federal minimum standards in several respects relevant to Eliquis coverage.

Continuity of Care During Formulary Changes

Under M.G.L. Chapter 176O, if BCBS MA removes Eliquis from the formulary mid-year or moves it to a higher tier, existing patients on a stable dose must be given a transition fill (typically 30 days) and must be notified at least 60 days before the change [7]. This protection prevents abrupt coverage loss for patients on chronic anticoagulation.

Emergency Dispensing

Massachusetts pharmacy law allows pharmacists to dispense a 30-day emergency supply of a maintenance medication, including apixaban, when a PA lapse or administrative delay would interrupt therapy. This is particularly relevant over holidays or when a PA renewal is pending [7].

Practical Checklist: Getting Eliquis Covered Through BCBS MA

Use this checklist before and during the authorization process:

1. Verify your formulary tier. Log in to bluecrossma.org or call member services; confirm whether PA is required for your specific plan and plan year.
2. Confirm your diagnosis matches an FDA-approved indication. The ICD-10 code on the prescription must align with an indication in the FDA label [1].
3. Have your prescriber prepare PA documentation. Include diagnosis, lab or imaging results, dose rationale, and at least one guideline citation [6][10][11].
4. Check the ACC/AHA Class I recommendation letter. A one-page letter citing the 2023 ACC/AHA guideline [6] and ARISTOTLE [2] data is often sufficient for atrial fibrillation PA approvals.
5. Apply for the BMS/Pfizer copay card. Even if approved, the manufacturer card can reduce your cost to $10 per month on commercial plans.
6. Set a PA renewal reminder. Most BCBS MA PA approvals for chronic conditions are valid for 12 months. Renewal must be initiated before expiration to avoid a coverage gap.
7. Know your appeal rights. Massachusetts law guarantees internal appeal + external IRO review + Division of Insurance complaint as three escalating options [7].